Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
NOXXON Pharma N.V. hereby announces the launch and terms of a share capital increase with shareholders’ preferential rights for an amount of up to € 3.9 million.
Humira generates about 60% of AbbVie’s annual revenue but is expected to lose patent protection in 2023.
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Medtronic plc announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc.
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
The board of directors of Medtronic plc approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share.